I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international medical scientific information about Oncology for Healthcare Professionals.

I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information for patients, caregivers and the general public.

Country-specific medical scientific information

Country-specific medical scientific information

Country-specific medical scientific information for Healthcare Professionals.

This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

ESMO Asia 2018

European Society for Medical Oncology Asia Congress 2018

The annual ESMO Asia Congress 2018 took place on 23rd–25th November in Singapore. At the congress, Boehringer Ingelheim presented two publications showcasing our advances in the treatment of lung cancer, including real-world data on sequential EGFR TKI treatment.

Publications

Please see downloadable versions below.

Filter by:
Presentation Type
  • All presentation types
  • Oral Presentation
  • Poster Presentation
  • e-Presentation
Tumour Type
  • All tumour types
Friday 23rd November 2018
Afatinib* followed by osimertinib in real-world patients with EGFR mutation-positive NSCLC: an observational study (GioTag)
Author(s): Hochmair et al.
Oral Presentation
Tumour Type(s): NSCLC
Presentation Number: LBA7
There are no publications which meet your criteria on this date
Saturday 24th November 2018
Afatinib in chemotherapy pre-treated EGFR mutation-positive NSCLC
Author(s): Thongprasert et al.
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: 474P
There are no publications which meet your criteria on this date

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

 

© 2018 Boehringer Ingelheim International GmbH. All rights reserved.

 Last updated: November 2018